Symposia: Allogeneic Transplantation: Acute and Chronic GVHD and Immune Reconstitution
Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Research, Clinical trials, Translational Research, Clinical Research, Genomics, Treatment Considerations, Biological therapies, Real-world evidence, Immunotherapy, Adverse Events, Registries, Computational biology, Biological Processes, Technology and Procedures, Study Population, Human, Transplantation (Allogeneic and Autologous), Machine learning, Omics technologies
Type: Oral
Hematology Disease Topics & Pathways:
Research, Clinical trials, Translational Research, Clinical Research, Genomics, Treatment Considerations, Biological therapies, Real-world evidence, Immunotherapy, Adverse Events, Registries, Computational biology, Biological Processes, Technology and Procedures, Study Population, Human, Transplantation (Allogeneic and Autologous), Machine learning, Omics technologies
Saturday, December 7, 2024: 4:00 PM-5:30 PM
Room 6CF
(San Diego Convention Center)
Moderators:
John Levine, MD, MS, Mount Sinai School of Medicine
and
Brian C. Shaffer, MD, MS, Memorial Sloan Kettering Cancer Center
Disclosures:
Levine: Bluebird Bio: Consultancy; Editas: Consultancy; Forte Biosciences: Consultancy; Inhibrx: Consultancy; Maat Pharma: Consultancy; Mesoblast: Consultancy; Novartis: Consultancy; X4: Consultancy; Ironwood: Consultancy; Calliditas: Consultancy; Viracor: Patents & Royalties: GVHD biomarker patent. Shaffer: Hansa Biopharma: Consultancy.
4:00 PM
4:15 PM
4:45 PM
5:00 PM
5:15 PM
See more of: Oral and Poster Abstracts
*signifies non-member of ASH